window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

targeted therapy

  • Cell & Gene Therapy,Clinical Development,Oncology,Technology and platforms

    N4 Pharma and SRI demonstrate targeted Nuvec delivery to lung cancer cells

    N4 Pharma has reported new data from its collaboration with [...]

    September 24, 2025
  • Clinical Development,Clinical Trials,Pharmaceuticals and therapeutics,Precision medicine,Rare Diseases

    A potential first-in-class treatment for children with achondroplasia is now in clinical testing

    Tyra Biosciences has dosed the first child in BEACH301, its [...]

    August 22, 2025
  • CDMOs & Manufacturing,Clinical Trials,Drug Development,Partnerships & Funding

    ITM secures $262.5M financing from Blue Owl to drive US launch of radiopharmaceutical for neuroendocrine tumors

    Landmark debt deal enables commercial readiness for ITM-11, supports pipeline [...]

    May 27, 2025
  • Drug Development

    SOTIO’s SOT109 targets CDH17 in colorectal cancer: A new ADC contender emerges

    SOTIO’s lead candidate, SOT109, is generating buzz in the ADC [...]

    May 6, 2025
  • Drug Development,Partnerships & Funding

    Er-Kim to distribute Nerlynx in CIS and Eastern Europe to improve HER2-positive breast cancer treatment access

    May 5, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top